Cargando…

Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy

BACKGROUND: Monocytes are increasingly implicated in the inflammatory consequences of HIV-1 disease, yet their phenotype following antiretroviral therapy (ART) initiation is incompletely defined. Here, we define more completely monocyte phenotype both prior to ART initiation and during 48 weeks of A...

Descripción completa

Detalles Bibliográficos
Autores principales: McCausland, Marie R., Juchnowski, Steven M., Zidar, David A., Kuritzkes, Daniel R., Andrade, Adriana, Sieg, Scott F., Lederman, Michael M., Funderburg, Nicholas T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591977/
https://www.ncbi.nlm.nih.gov/pubmed/26430882
http://dx.doi.org/10.1371/journal.pone.0139474
_version_ 1782393138178949120
author McCausland, Marie R.
Juchnowski, Steven M.
Zidar, David A.
Kuritzkes, Daniel R.
Andrade, Adriana
Sieg, Scott F.
Lederman, Michael M.
Funderburg, Nicholas T.
author_facet McCausland, Marie R.
Juchnowski, Steven M.
Zidar, David A.
Kuritzkes, Daniel R.
Andrade, Adriana
Sieg, Scott F.
Lederman, Michael M.
Funderburg, Nicholas T.
author_sort McCausland, Marie R.
collection PubMed
description BACKGROUND: Monocytes are increasingly implicated in the inflammatory consequences of HIV-1 disease, yet their phenotype following antiretroviral therapy (ART) initiation is incompletely defined. Here, we define more completely monocyte phenotype both prior to ART initiation and during 48 weeks of ART. METHODS: Cryopreserved peripheral blood mononuclear cells (PBMCs) were obtained at baseline (prior to ART initiation) and at weeks 12, 24, and 48 of treatment from 29 patients participating in ACTG clinical trial A5248, an open label study of raltegravir/emtricitibine/tenofovir administration. For comparison, cryopreserved PBMCs were obtained from 15 HIV-1 uninfected donors, each of whom had at least two cardiovascular risk factors. Thawed samples were stained for monocyte subset markers (CD14 and CD16), HLA-DR, CCR2, CX3CR1, CD86, CD83, CD40, CD38, CD36, CD13, and CD163 and examined using flow cytometry. RESULTS: In untreated HIV-1 infection there were perturbations in monocyte subset phenotypes, chiefly a higher frequency and density (mean fluorescence intensity–MFI) of HLA-DR (%-p = 0.004, MFI-p = .0005) and CD86 (%-p = 0.012, MFI-p = 0.005) expression and lower frequency of CCR2 (p = 0.0002) expression on all monocytes, lower CCR2 density on inflammatory monocytes (p = 0.045) when compared to the expression and density of these markers in controls’ monocytes. We also report lower expression of CX3CR1 (p = 0.014) on patrolling monocytes at baseline, compared to levels seen in controls. After ART, these perturbations tended to improve, with decreasing expression and density of HLA-DR and CD86, increasing CCR2 density on inflammatory monocytes, and increasing expression and density of CX3CR1 on patrolling monocytes. CONCLUSIONS: In HIV-1 infected patients, ART appears to attenuate the high levels of activation (HLA-DR, CD86) and to increase expression of the chemokine receptors CCR2 and CX3CR1 on monocyte populations. Circulating monocyte phenotypes are altered in untreated infection and tend to normalize with ART; the role of these cells in the inflammatory environment of HIV-1 infection warrants further study.
format Online
Article
Text
id pubmed-4591977
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45919772015-10-09 Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy McCausland, Marie R. Juchnowski, Steven M. Zidar, David A. Kuritzkes, Daniel R. Andrade, Adriana Sieg, Scott F. Lederman, Michael M. Funderburg, Nicholas T. PLoS One Research Article BACKGROUND: Monocytes are increasingly implicated in the inflammatory consequences of HIV-1 disease, yet their phenotype following antiretroviral therapy (ART) initiation is incompletely defined. Here, we define more completely monocyte phenotype both prior to ART initiation and during 48 weeks of ART. METHODS: Cryopreserved peripheral blood mononuclear cells (PBMCs) were obtained at baseline (prior to ART initiation) and at weeks 12, 24, and 48 of treatment from 29 patients participating in ACTG clinical trial A5248, an open label study of raltegravir/emtricitibine/tenofovir administration. For comparison, cryopreserved PBMCs were obtained from 15 HIV-1 uninfected donors, each of whom had at least two cardiovascular risk factors. Thawed samples were stained for monocyte subset markers (CD14 and CD16), HLA-DR, CCR2, CX3CR1, CD86, CD83, CD40, CD38, CD36, CD13, and CD163 and examined using flow cytometry. RESULTS: In untreated HIV-1 infection there were perturbations in monocyte subset phenotypes, chiefly a higher frequency and density (mean fluorescence intensity–MFI) of HLA-DR (%-p = 0.004, MFI-p = .0005) and CD86 (%-p = 0.012, MFI-p = 0.005) expression and lower frequency of CCR2 (p = 0.0002) expression on all monocytes, lower CCR2 density on inflammatory monocytes (p = 0.045) when compared to the expression and density of these markers in controls’ monocytes. We also report lower expression of CX3CR1 (p = 0.014) on patrolling monocytes at baseline, compared to levels seen in controls. After ART, these perturbations tended to improve, with decreasing expression and density of HLA-DR and CD86, increasing CCR2 density on inflammatory monocytes, and increasing expression and density of CX3CR1 on patrolling monocytes. CONCLUSIONS: In HIV-1 infected patients, ART appears to attenuate the high levels of activation (HLA-DR, CD86) and to increase expression of the chemokine receptors CCR2 and CX3CR1 on monocyte populations. Circulating monocyte phenotypes are altered in untreated infection and tend to normalize with ART; the role of these cells in the inflammatory environment of HIV-1 infection warrants further study. Public Library of Science 2015-10-02 /pmc/articles/PMC4591977/ /pubmed/26430882 http://dx.doi.org/10.1371/journal.pone.0139474 Text en © 2015 McCausland et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
McCausland, Marie R.
Juchnowski, Steven M.
Zidar, David A.
Kuritzkes, Daniel R.
Andrade, Adriana
Sieg, Scott F.
Lederman, Michael M.
Funderburg, Nicholas T.
Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
title Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
title_full Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
title_fullStr Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
title_full_unstemmed Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
title_short Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
title_sort altered monocyte phenotype in hiv-1 infection tends to normalize with integrase-inhibitor-based antiretroviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591977/
https://www.ncbi.nlm.nih.gov/pubmed/26430882
http://dx.doi.org/10.1371/journal.pone.0139474
work_keys_str_mv AT mccauslandmarier alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy
AT juchnowskistevenm alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy
AT zidardavida alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy
AT kuritzkesdanielr alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy
AT andradeadriana alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy
AT siegscottf alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy
AT ledermanmichaelm alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy
AT funderburgnicholast alteredmonocytephenotypeinhiv1infectiontendstonormalizewithintegraseinhibitorbasedantiretroviraltherapy